|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010583,
umls-concept:C0030705,
umls-concept:C0038250,
umls-concept:C0077973,
umls-concept:C0079459,
umls-concept:C0178602,
umls-concept:C0179926,
umls-concept:C0300926,
umls-concept:C0392920,
umls-concept:C1274040,
umls-concept:C1407029,
umls-concept:C1627892,
umls-concept:C1704419,
umls-concept:C2603343
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2006-4-5
|
|
pubmed:abstractText |
A study was conducted to compare the efficiency and toxicity of two peripheral blood stem cell (PBSC) mobilization procedures for newly diagnosed patients with multiple myeloma. Patients from group 1 (n=51) were treated by high-dose cyclophosphamide (HD-CY) plus G-CSF (5 microg/kg/day), and the second group (n=31) by VAD regimen plus G-CSF administration (10 microg/kg/day). Successful mobilization, defined by a minimal count of 2.5 x 10(6) CD34(+) cells/kg collected, was achieved in 96 and 90% of patients in groups 1 and 2, respectively (P=0.15). The mean peripheral blood CD34(+) cells concentration and the mean CD34(+) cells/kg collected were higher in group 2 than in the group 1 (P=0.05). The mean number of leukaphereses necessary to collect a count of 2.5 x 10(6) CD34(+) cells/kg was reduced in group 2 compared to group 1. Adverse events, blood products consumption and time spent in the hospital were significantly greater after HD-CY. In conclusion, VAD plus a G-CSF dose of 10 microg/kg administration seems preferential to HD-CY plus a G-CSF dose of 5 microg/kg for PBSC collection because of equivalent or better efficiency in stem cell mobilization, strong favorable toxicity profile and reduced cost.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
pubmed-author:AudatFF,
pubmed-author:AzaguryMM,
pubmed-author:Cavazzana-CalvoMM,
pubmed-author:Dal CortivoLL,
pubmed-author:DamajGG,
pubmed-author:DelarueRR,
pubmed-author:GhezDD,
pubmed-author:HermineOO,
pubmed-author:JondeauKK,
pubmed-author:LefrèreFF,
pubmed-author:MaillardNN,
pubmed-author:MisbahiRR,
pubmed-author:RibeilJ AJA,
pubmed-author:SuarezFF,
pubmed-author:VaretBB,
pubmed-author:ZoharSS
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
725-9
|
|
pubmed:meshHeading |
pubmed-meshheading:16518433-Antigens, CD34,
pubmed-meshheading:16518433-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16518433-Cell Separation,
pubmed-meshheading:16518433-Cyclophosphamide,
pubmed-meshheading:16518433-Dexamethasone,
pubmed-meshheading:16518433-Doxorubicin,
pubmed-meshheading:16518433-Female,
pubmed-meshheading:16518433-Flow Cytometry,
pubmed-meshheading:16518433-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:16518433-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:16518433-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16518433-Humans,
pubmed-meshheading:16518433-Male,
pubmed-meshheading:16518433-Middle Aged,
pubmed-meshheading:16518433-Multiple Myeloma,
pubmed-meshheading:16518433-Stem Cells,
pubmed-meshheading:16518433-Time Factors,
pubmed-meshheading:16518433-Treatment Outcome,
pubmed-meshheading:16518433-Vincristine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
|
|
pubmed:affiliation |
Service de Biothérapies, Hôpital Necker, AP-HP, Paris, France. francois.lefrere@nck.aphp.fr
|
|
pubmed:publicationType |
Journal Article
|
